NCT07010250 Epithelial Dysmetabolism and Renal Fibrosis in ANCA Vasculitis
| NCT ID | NCT07010250 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Condition | ANCA Associated Vasculitis |
| Study Type | OBSERVATIONAL |
| Enrollment | 146 participants |
| Start Date | 2025-11-03 |
| Primary Completion | 2029-11-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 146 participants in total. It began in 2025-11-03 with a primary completion date of 2029-11-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The project is to explore in humans the hypothesis of the link between the alteration of tubulo-interstitial metabolism and the rate of deterioration of renal function by comparing various nephropathies.
Eligibility Criteria
Inclusion Criteria: * Patients with an indication for initial diagnostic PBR on native kidney * 18 ans ≥ Age ≤ 90 ans * Affiliation to french health insurance * Patient having given consent For the ANCA vasculitis group: • Diagnosis of ANCA vasculitis retained on renal biopsy with ANCA anti-proteinase 3 (PR3) or ANCA anti-myeloperoxidase (MPO) For the control groups: • Diagnosis retained after the renal biopsy * Interstitial Nephritis * Or glomerular nephropathy such as minimal change nephropathy * Or Segmental hyalinosis in itscollapsing form * Or Extramembranous Glomerulopathy, * Or glomerulopathy with mesangial IgA deposits * Or diabetic nephropathy. Exclusion Criteria: * Kidney transplant patient * Patient on dialysis (hemodialysis or peritoneal dialysis) * Patient under legal protection, guardianship or curatorship * Pregnancy or breastfeeding * Enrollement in an interventional study except studies relating to ANCA vasculitis and nephropathy with mesangial IgA deposits.
Contact & Investigator
Marine LIVROZET
PRINCIPAL INVESTIGATOR
Assistance Publique - Hôpitaux de Paris
Frequently Asked Questions
Who can join the NCT07010250 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 90 Years, studying ANCA Associated Vasculitis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07010250 currently recruiting?
Yes, NCT07010250 is actively recruiting participants. Contact the research team at maxime.brussieux@aphp.fr for enrollment information.
Where is the NCT07010250 trial being conducted?
This trial is being conducted at Paris, France.
Who is sponsoring the NCT07010250 clinical trial?
NCT07010250 is sponsored by Assistance Publique - Hôpitaux de Paris. The principal investigator is Marine LIVROZET at Assistance Publique - Hôpitaux de Paris. The trial plans to enroll 146 participants.